Suppr超能文献

对于患有勃起功能障碍的日本糖尿病男性患者,20毫克伐地那非的疗效优于10毫克伐地那非。

Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction.

作者信息

Ishii Nobuhisa, Nagao Koichi, Fujikawa Keita, Tachibana Takashi, Iwamoto Yasuhiko, Kamidono Sadao

机构信息

Department of Urology, Toho University School of Medicine, Tokyo, Japan.

出版信息

Int J Urol. 2006 Aug;13(8):1066-72. doi: 10.1111/j.1442-2042.2006.01480.x.

Abstract

AIM

Vardenafil is a highly selective and potent phosphodiesterase type-5 inhibitor for the treatment of erectile dysfunction (ED). The efficacy of vardenafil has been demonstrated in a broad range of ED populations, but has not yet been assessed in Japanese patients with diabetes mellitus (DM), although DM is frequently associated with difficult-to-treat ED. This is the first study to investigate whether high-dose vardenafil (20 mg) can demonstrate superior efficacy to the usual dose (10 mg) in this subpopulation in Japan.

METHODS

The study was a randomized, placebo-controlled, double-blind, multi-centre, parallel group comparison 12-week study. Following 4 weeks observation period, 778 patients aged 26-64 years old with ED and DM (HbA1c >12% at screening was excluded) both of more than 3 years duration were randomly allocated to one of the three groups, vardenafil 10 mg, 20 mg, or placebo (randomization ratio 3:3:1). Erectile function (EF) domain score of the International Index of Erectile Function was estimated as the primary efficacy parameter.

RESULTS

Vardenafil 10 and 20 mg both significantly improved the EF domain score from 13.6 and 13.9 at baseline to 21.8 and 22.9 at last observation carried forward (LOCF), respectively, compared to placebo (13.7 at baseline to 16.3 at LOCF; p<0.0001). In addition, vardenafil 20 mg demonstrated superior efficacy to 10 mg (p<0.05), and the difference was more evident in severe ED patients (baseline EF domain score <11). The safety profile was comparable between these two doses (drug-related adverse events: 6.6, 22.0 and 24.2% in placebo, vardenafil 10 mg, and 20 mg arms, respectively). The most common adverse events were hot flush, headache and nasal congestion, which were mild in intensity and transient, and are known to be common to PDE5 inhibitors.

CONCLUSION

In Japanese men with DM and ED, vardenafil 10 mg and 20 mg were effective in improving erectile function with comparable safety profiles. Vardenafil 20 mg demonstrated superior efficacy compared with 10 mg, suggesting incremental clinical benefit in using the higher dose in this difficult-to-treat population.

摘要

目的

伐地那非是一种高选择性且强效的5型磷酸二酯酶抑制剂,用于治疗勃起功能障碍(ED)。伐地那非在广泛的ED人群中已证实其疗效,但在日本糖尿病(DM)患者中尚未进行评估,尽管DM常伴有难以治疗的ED。这是第一项研究,旨在调查在日本这一亚组人群中,高剂量伐地那非(20毫克)是否比常用剂量(10毫克)具有更优疗效。

方法

该研究为一项随机、安慰剂对照、双盲、多中心、平行组比较的12周研究。经过4周观察期后,将778例年龄在26 - 64岁、患有ED且DM病程超过3年(排除筛查时糖化血红蛋白A1c>12%者)的患者随机分配至三组之一:伐地那非10毫克组、20毫克组或安慰剂组(随机化比例为3:3:1)。将国际勃起功能指数的勃起功能(EF)领域评分作为主要疗效参数进行评估。

结果

与安慰剂组(基线时为13.7,末次观察结转时为16.3;p<0.0001)相比,伐地那非10毫克组和20毫克组的EF领域评分分别从基线时的13.6和13.9显著提高至末次观察结转时的21.8和22.9。此外,伐地那非20毫克组的疗效优于10毫克组(p<0.05),且在重度ED患者(基线EF领域评分<11)中差异更为明显。这两种剂量的安全性相当(药物相关不良事件:安慰剂组、伐地那非10毫克组和20毫克组分别为6.6%、22.0%和24.2%)。最常见的不良事件为潮热、头痛和鼻塞,强度较轻且为一过性,已知是5型磷酸二酯酶抑制剂常见的不良反应。

结论

在患有DM和ED的日本男性中,伐地那非10毫克和20毫克在改善勃起功能方面均有效,且安全性相当。伐地那非20毫克组的疗效优于10毫克组,表明在这一难以治疗的人群中使用更高剂量具有额外的临床益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验